Current status of the taxanes as adjuvant therapy for breast cancer

Clifford Hudis, Heather McArthur, Chau Dang

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Adjuvant chemotherapy for breast cancer reduces the risks of recurrence and death in many subsets of patients. The quest for better regimens, defined as both more effective and less toxic has led to numerous clinical trials testing the taxanes in the adjuvant setting. These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research.

Original languageEnglish (US)
Pages (from-to)132-135
Number of pages4
Issue number2 SUPPL.
StatePublished - 2007
Externally publishedYes


  • Adjuvant therapy
  • Breast cancer
  • Taxanes

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Cancer Research


Dive into the research topics of 'Current status of the taxanes as adjuvant therapy for breast cancer'. Together they form a unique fingerprint.

Cite this